+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines



Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines



Cancer ChemoTherapy and Pharmacology 26(1): 79-81



Combretastatin A4, a novel anti-mitotic agent was effective against two P388 cell lines with acquired resistance to daunorubicin. In contrast, Combretastatin A1, a close structural analogue of A4, showed a high degree of cross-resistance. Combretastatin A1 was also more efficient at increasing intracellular daunorubicin concentrations in both resistant cell lines. Neither agent was capable of altering anthracycline accumulation in the parental (sensitive) cell line. We propose that the cross-resistance to Combretastatin A1 occurs, at least in part, as a result of the increased affinity of the drug-efflux process operative in these resistant cells for Combretastatin A1 vs Combretastatin A4. Hence, Combretastatin A4 may play a role in the treatment of tumours with acquired resistance to the anthracycline antibiotics.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039822898

Download citation: RISBibTeXText

PMID: 2322992

DOI: 10.1007/bf02940301


Related references

Increased activity of atp driven proton pumps in plasma membranes of daunorubicin resistant ehrlich ea and p388 cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 32: 431, 1991

Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures. Cancer ChemoTherapy and Pharmacology 11(2): 113-116, 1983

Evidence of difference between cytotoxicity, cell cycle and morphonuclear effects of polyamines on sensitive and multidrug resistant P388 cell lines. Anticancer Research 17(3c): 2057-2064, 1997

Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells. British Journal of Cancer 53(4): 561-566, 1986

Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Research 49(1): 58-62, 1989

Effect of calphostin a specific inhibitor of protein kinase c pkc on daunorubicin transport and cytotoxicity in multidrug resistant mdr p388 adr and hl60 ar cells. Proceedings of the American Association for Cancer Research Annual Meeting 33: 458, 1992

Relative cytotoxicity and P-glycoprotein binding avidity of idarubicin, daunorubicin and mitoxantrone in multidrug resistant cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 34: 25, 1993

Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP. Anticancer Research 9(3): 567-574, 1989

Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sciences 67(10): 1207-1218, 2000

Increased plasma membrane traffic in daunorubicin resistant p388 leukemic cells effect of daunorubicin and verapamil. British Journal of Cancer 56(6): 747-751, 1987

Effect of verapamil and buthionine sulfoximine bso on daunorubicin dnr cytotoxicity of multidrug resistant human melanoma cell lines overexpressing p glycoprotein and glutathione s transferases. Proceedings of the American Association for Cancer Research Annual Meeting 33: 554, 1992

Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Research 46(6): 2978-2983, 1986

Differential alteration of cellular lipids in drug sensitive and resistant P388 leukemia cells by clofibrate: effects on mitoxantrone cytotoxicity. Tumori 77(2): 105-111, 1991